These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 38580165)

  • 21. The effect of VMAT2 inhibitor GZ-793A on the reinstatement of methamphetamine-seeking in rats.
    Alvers KM; Beckmann JS; Zheng G; Crooks PA; Dwoskin LP; Bardo MT
    Psychopharmacology (Berl); 2012 Nov; 224(2):255-62. PubMed ID: 22638813
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methamphetamine self-administration acutely decreases monoaminergic transporter function.
    McFadden LM; Stout KA; Vieira-Brock PL; Allen SC; Nielsen SM; Wilkins DG; Hanson GR; Fleckenstein AE
    Synapse; 2012 Mar; 66(3):240-5. PubMed ID: 22120988
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lobelane analogues containing 4-hydroxy and 4-(2-fluoroethoxy) aromatic substituents: Potent and selective inhibitors of [(3)H]dopamine uptake at the vesicular monoamine transporter-2.
    Joolakanti SR; Nickell JR; Janganati V; Zheng G; Dwoskin LP; Crooks PA
    Bioorg Med Chem Lett; 2016 May; 26(10):2422-2427. PubMed ID: 27080180
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Methamphetamine administration reduces hippocampal vesicular monoamine transporter-2 uptake.
    Rau KS; Birdsall E; Volz TJ; Riordan JA; Baucum AJ; Adair BP; Bitter R; Gibb JW; Hanson GR; Fleckenstein AE
    J Pharmacol Exp Ther; 2006 Aug; 318(2):676-82. PubMed ID: 16687477
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduced vesicular storage of dopamine exacerbates methamphetamine-induced neurodegeneration and astrogliosis.
    Guillot TS; Shepherd KR; Richardson JR; Wang MZ; Li Y; Emson PC; Miller GW
    J Neurochem; 2008 Sep; 106(5):2205-17. PubMed ID: 18643795
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PACAP38 increases vesicular monoamine transporter 2 (VMAT2) expression and attenuates methamphetamine toxicity.
    Guillot TS; Richardson JR; Wang MZ; Li YJ; Taylor TN; Ciliax BJ; Zachrisson O; Mercer A; Miller GW
    Neuropeptides; 2008 Aug; 42(4):423-34. PubMed ID: 18533255
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lobelane decreases methamphetamine self-administration in rats.
    Neugebauer NM; Harrod SB; Stairs DJ; Crooks PA; Dwoskin LP; Bardo MT
    Eur J Pharmacol; 2007 Sep; 571(1):33-8. PubMed ID: 17612524
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A rapid oxidation and persistent decrease in the vesicular monoamine transporter 2 after methamphetamine.
    Eyerman DJ; Yamamoto BK
    J Neurochem; 2007 Nov; 103(3):1219-27. PubMed ID: 17683483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure.
    McFadden LM; Hadlock GC; Allen SC; Vieira-Brock PL; Stout KA; Ellis JD; Hoonakker AJ; Andrenyak DM; Nielsen SM; Wilkins DG; Hanson GR; Fleckenstein AE
    J Pharmacol Exp Ther; 2012 Feb; 340(2):295-303. PubMed ID: 22034657
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human methamphetamine pharmacokinetics simulated in the rat: behavioral and neurochemical effects of a 72-h binge.
    Kuczenski R; Segal DS; Melega WP; Lacan G; McCunney SJ
    Neuropsychopharmacology; 2009 Oct; 34(11):2430-41. PubMed ID: 19571794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluoroethoxy-1,4-diphenethylpiperidine and piperazine derivatives: Potent and selective inhibitors of [
    Hankosky ER; Joolakanti SR; Nickell JR; Janganati V; Dwoskin LP; Crooks PA
    Bioorg Med Chem Lett; 2017 Dec; 27(24):5467-5472. PubMed ID: 29153425
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Methamphetamine-induced dopamine transporter complex formation and dopaminergic deficits: the role of D2 receptor activation.
    Hadlock GC; Chu PW; Walters ET; Hanson GR; Fleckenstein AE
    J Pharmacol Exp Ther; 2010 Oct; 335(1):207-12. PubMed ID: 20622144
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Defunctionalized lobeline analogues: structure-activity of novel ligands for the vesicular monoamine transporter.
    Zheng G; Dwoskin LP; Deaciuc AG; Norrholm SD; Crooks PA
    J Med Chem; 2005 Aug; 48(17):5551-60. PubMed ID: 16107155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Age-dependent differences in dopamine transporter and vesicular monoamine transporter-2 function and their implications for methamphetamine neurotoxicity.
    Volz TJ; Farnsworth SJ; Rowley SD; Hanson GR; Fleckenstein AE
    Synapse; 2009 Feb; 63(2):147-51. PubMed ID: 19021208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quinolyl analogues of norlobelane: novel potent inhibitors of [(3)H]dihydrotetrabenazine binding and [(3)H]dopamine uptake at the vesicular monoamine transporter-2.
    Ding D; Nickell JR; Dwoskin LP; Crooks PA
    Bioorg Med Chem Lett; 2015 Jul; 25(13):2613-6. PubMed ID: 25991431
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine.
    Frey K; Kilbourn M; Robinson T
    Eur J Pharmacol; 1997 Sep; 334(2-3):273-9. PubMed ID: 9369358
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Methamphetamine treatment during development attenuates the dopaminergic deficits caused by subsequent high-dose methamphetamine administration.
    McFadden LM; Hoonakker AJ; Vieira-Brock PL; Stout KA; Sawada NM; Ellis JD; Allen SC; Walters ET; Nielsen SM; Gibb JW; Alburges ME; Wilkins DG; Hanson GR; Fleckenstein AE
    Synapse; 2011 Aug; 65(8):771-7. PubMed ID: 21190217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Role of Biogenic Amine Transporters in Trace Amine-Associated Receptor 1 Regulation of Methamphetamine-Induced Neurotoxicity.
    Miner NB; Phillips TJ; Janowsky A
    J Pharmacol Exp Ther; 2019 Oct; 371(1):36-44. PubMed ID: 31320495
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lobeline effects on tonic and methamphetamine-induced dopamine release.
    Wilhelm CJ; Johnson RA; Eshleman AJ; Janowsky A
    Biochem Pharmacol; 2008 Mar; 75(6):1411-5. PubMed ID: 18191815
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epothilone D prevents binge methamphetamine-mediated loss of striatal dopaminergic markers.
    Killinger BA; Moszczynska A
    J Neurochem; 2016 Feb; 136(3):510-25. PubMed ID: 26465779
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.